- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03084237
Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer
June 4, 2022 updated by: Shanghai Henlius Biotech
Double-blind, Randomized, Multicenter, Phase III Clinical Study to Compare the Efficacy and to Evaluate the Safety and Immunogenicity of Trastuzumab Biosimilar HLX02 and EU-sourced Herceptin® in Previously Untreated HER2 Overexpressing Metastatic Breast Cancer
This is a Phase III, double-blind, randomized multicenter study to compare the efficacy and to evaluate the safety and immunogenicity of HLX02 and European Union (EU)-sourced Herceptin® in patients with human epidermal growth factor receptor 2 (HER2)-positive, locally recurrent or previously untreated metastatic breast cancer.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a Phase III, double-blind, randomized multicenter study to compare the efficacy and to evaluate the safety and immunogenicity of HLX02 and European Union (EU)-sourced Herceptin® in patients with human epidermal growth factor receptor 2 (HER2)-positive, recurrent or previously untreated metastatic breast cancer.
Eligible patients will be assessed centrally for HER2 status and the presence of at least one measurable target lesion before randomization.
Patients will undergo a tumor assessment for evaluation of response according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) every 6 weeks up to 24 weeks (regardless of the number of cycles actually given); thereafter, assessments will be done every 9 weeks (after Cycles 11, 14, and 17) or earlier in the case of clinical signs of progression.
Study Type
Interventional
Enrollment (Actual)
649
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
- Chinese PLA General Hospital
-
Beijing, China
- Cancer Hospital, Chinese Academy of Medical Sciences
-
Beijing, China
- Beijing Cancer Hospital
-
Beijing, China
- Peking Union Medical College Hospital
-
-
Anhui
-
Hefei, Anhui, China
- The First Affiliated Hospital of Anhui Medical University
-
Hefei, Anhui, China
- The Second Hospital of Anhui Medical University
-
-
Beijing
-
Beijing, Beijing, China
- Beijing Friendship Hospital, Capital Medical University
-
-
Chongqing
-
Chongqing, Chongqing, China
- Chongqing University Cancer Hospital
-
-
Fujian
-
Fuzhou, Fujian, China
- Fujian Medical University Union Hospital
-
Fuzhou, Fujian, China
- Fujian Cancer Hospital
-
Xiamen, Fujian, China
- The First Affiliated Hospital of Xiamen University
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
-
Guangzhou, Guangdong, China
- Affiliated Cancer Hospital and Institute of Guangzhou Medical University
-
Guangzhou, Guangdong, China
- First Affiliated Hospital of Guangzhou University of TMC
-
Guangzhou, Guangdong, China
- The First Affiliated Hospital of Guangdong College of Pharmacy
-
Guanzhou, Guangdong, China
- Sun Yat-sen University, Cancer Center
-
Shenzhen, Guangdong, China
- The University of Hong Kong-Shenzhen Hospital
-
Zhanjiang, Guangdong, China
- Affiliated Hospital of Guangdong Medical University
-
-
Guangxi
-
Liuzhou, Guangxi, China
- Liuzhou General Hospital
-
Nanning, Guangxi, China
- Guangxi Medical University Affiliated Tumor Hospital
-
-
Hebei
-
Baoding, Hebei, China
- Affiliated Hospital of Hebei University
-
Cangzhou, Hebei, China
- Hebei Cangzhou Central Hospital
-
Shijiazhuang, Hebei, China
- The Fourth Hospital of Hebei Medical University
-
-
Heilongjiang
-
Harbin, Heilongjiang, China
- Harbin Medical University Cancer Hospital
-
-
Henan
-
Zhengzhou, Henan, China
- Henan Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, China
- Hubei Cancer Hospital
-
Wuhan, Hubei, China
- Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
-
Wuhan, Hubei, China
- Union Hospital, Tongji Medical College of Huazhong University of Science & Technology
-
-
Hunan
-
Changsha, Hunan, China
- The Third Xiangya Hospital of Central South University
-
Changsha, Hunan, China
- The 2nd Xiangya Hospital of Central South University
-
-
Inner Mongolia
-
Chifeng, Inner Mongolia, China
- Neimenggu Chifeng Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Jiangsu Province Hospital
-
Nanjing, Jiangsu, China
- Jiangsu Cancer Hospital
-
Nanjing, Jiangsu, China
- Nanjing Bayi Hospital
-
Nanjing, Jiangsu, China
- The Affiliated Drum Tower Hospital of Nanjing University
-
Nantong, Jiangsu, China
- Nantong Tumor Hospital
-
Wuxi, Jiangsu, China
- Wuxi 4th People's Hospital
-
Xuzhou, Jiangsu, China
- XuZhou Central Hospital
-
Yangzhou, Jiangsu, China
- Northern Jiangsu People's Hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, China
- The Second Affiliated Hospital Of NanChang University
-
-
Jilin
-
Chang chun, Jilin, China
- The First Hospital of Jilin University
-
Changchun, Jilin, China
- Jilin Cancer Hospital
-
Changchun, Jilin, China
- Jilin Province People's Hospital
-
-
Liaoning
-
Dalian, Liaoning, China
- The Second Hospital of Dalian Medical University
-
Shenyang, Liaoning, China
- The First Hospital of China Medical University
-
Shenyang, Liaoning, China
- General Hospital of The Northern Theater of The Chinese People's Liberation Army
-
Shenyang, Liaoning, China
- Liaoning Cancer Hospital & Institute
-
-
Qinghai
-
Xining, Qinghai, China
- Affiliated Hospital of Qinghai University
-
-
Shandong
-
Jining, Shandong, China
- Affiliated hospital of Jining Medical University
-
-
Shangdong
-
Jinan, Shangdong, China
- Jinan Central Hospital
-
Yantai, Shangdong, China
- Yantai Yuhuangding Hospital
-
-
Shanghai
-
Shanghai, Shanghai, China
- Fudan University Shanghai Cancer Center
-
Shanghai, Shanghai, China
- Ruijin Hospital of Shanghai Jiaotong University School of Medicine
-
-
Shangxi
-
Xi'an, Shangxi, China
- Shannxi Provincial Tumor Hospital
-
-
Shanxi
-
Xi'an, Shanxi, China
- The First Affiliated Hospital of Xi'an Jiaotong University
-
Xi'an, Shanxi, China
- The 2nd Hospital of Xi'An Jiaotong University
-
-
Sichuan
-
Chengdu, Sichuan, China
- West China Hospital, Sichuan University
-
Nanchong, Sichuan, China
- Nanchong Central Hospital
-
-
Tianjing
-
Tianjing, Tianjing, China
- Tianjin Medical University Cancer Institute & Hospital
-
-
Yunnan
-
Kunming, Yunnan, China
- Yunnan cancer hospital
-
-
Zhejiang
-
HanGzhou, Zhejiang, China
- The First Affiliated Hospital, College of Medicine, Zhejiang University
-
Hangzhou, Zhejiang, China
- Zhejiang Cancer hospital
-
Hangzhou, Zhejiang, China
- Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
-
Hangzhou, Zhejiang, China
- The Second Affiliated Hospital of Zhejiang University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
- Patients have voluntarily agreed to participate and given written informed consent.
- Male or female ≥18 years of age on day of signing the informed consent form (ICF).
- Histologically or cytologically confirmed adenocarcinoma of the breast.
- Recurrent disease not amenable to curative surgery or radiation therapy, or metastatic disease with an indication for a taxane-containing therapy.
- Availability of formalin-fixed paraffin-embedded (FFPE) tissue block from the primary tumor, or a metastatic lesion, to confirm HER2-positivity by the central laboratory, based on FISH amplification ratio ≥2.0 or IHC score 3+, and for hormone status (ER/PgR) determination (local or central laboratory). If not possible, a fresh biopsy is required.
- No prior systemic anticancer agent such as chemotherapy, biological or targeted agent for metastatic disease with the exception of hormonal therapy, which must be stopped at least 2 weeks before randomization. Use of herbal remedies or traditional Chinese medicines for anticancer, hematologic or liver function, or anti-infective treatment must be stopped at the time of the ICF signature (at least 2 weeks before randomization).
- For patients with recurrent disease, prior neo-/adjuvant therapy containing trastuzumab and/or lapatinib must have been stopped at least 12 months before the diagnosis of recurrent (local or metastatic) disease. If trastuzumab/lapatinib was not used, prior neo-/adjuvant therapy with a taxane must have been stopped at least 6 months before the diagnosis of recurrent (local or metastatic) disease. If only other cytotoxics were given, they must be stopped at least 4 weeks before randomization. Any hormonal therapy must be stopped at the time of the ICF signature.
- Measurable disease (at least one measurable target lesion assessed by CIR; bone-only or central nervous system [CNS]-only metastases are not allowed).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- LVEF within institutional range of normal at baseline (within 42 days before randomization) as determined by either echocardiography (ECHO) or multigated acquisition (MUGA) scan.
- Adequate hematologic, hepatic and renal function as indicated by the following laboratory values:
- Absolute neutrophil count (ANC) ≥1,500/μL without granulocyte-colony stimulating factor (G-CSF) or other medical support
- Platelets ≥100,000/μL
- Hemoglobin ≥9 g/dL without transfusion or other medical support within 14 days
- Serum creatinine ≤1.5 x upper limit of normal (ULN) and creatinine clearance rate ≥50 mL/min, calculated according to Cockroft-Gault formula
- Serum total bilirubin ≤1.5 x ULN (unless the patient has documented ·Gilbert's syndrome) without any medical support within 14 days
- Serum aspartate aminotransferase/glutamicoxaloacetic transaminase (AST/SGOT) or serum alanine aminotransferase/glutamate-pyruvate transaminase (ALT/SGPT) ≤2.5 x ULN (≤5 x ULN in the case of liver metastases) provided alkaline phosphatase (ALK) is ≤2.5 x ULN. In the case of bone metastasis, serum ALK can be >2.5 x ULN if AST and ALT are ≤1.5 x ULN without any medical support within 14 days
- International normalized ratio (INR), and activated partial prothrombin time (aPTT) or partial prothrombin time (PTT) ≤1.5 x ULN.
- Estimated life expectancy ≥3 months.
- Female patients are eligible to enter and participate in the study if they are of: Non-childbearing potential. Childbearing potential, have a negative serum pregnancy test at Screening, are not breast feeding, and use highly-effective or acceptable contraceptive measures before study entry and throughout the study until 7 months after the last investigational/comparator product administration. Highly-effective or acceptable contraceptive measures.
- Male patients with partners of childbearing potential are eligible to enter and participate in the study if they, and their female partners, are willing to use highly-effective or acceptable contraceptive measures before study entry and throughout the study until 7 months after the last investigational/comparator product administration.
Exclusion Criteria
- Previously- or currently-treated (systemic chemotherapy, biological, or targeted agent, or any other anticancer agent) metastatic breast cancer with the exception of hormonal therapy.
- Known brain metastasis or other CNS metastasis that is either symptomatic or untreated. Central nervous system metastases that have been treated by complete resection and/or radiotherapy demonstrating stability or improvement are not an exclusion criterion provided they are stable as shown by computed tomography (CT) scan for at least 4 weeks before Screening without evidence of cerebral edema and no requirements for corticosteroids or anticonvulsants.
- Participation in another clinical study within 4 weeks before enrollment (3 months for studies involving monoclonal therapy) or the intention of participating in another clinical study during any part of the study period.
- History of other malignancy within the last 5 years, except for carcinoma in-situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin that has been previously treated with curative intent.
- Known history of human immunodeficiency virus (HIV). Clinically significant active infection requiring therapy; positive tests for hepatitis B; or hepatitis C.
- Underlying medical conditions or current severe, uncontrolled systemic disease that, in the Investigator's opinion, will make the administration of study drug hazardous. A major surgical procedure within 4 weeks prior to enrollment or anticipation of the need for major surgery during the course of study.
- Current uncontrolled hypertension (systolic >150 mmHg and/or diastolic >100 mmHg) or unstable angina.
- History of chronic heart failure based on any New York Heart Association (NYHA) criteria, or left ventricular hypertrophy. Current serious cardiac arrhythmia requiring treatment or clinically significant conduction defects as seen on electrocardiogram (ECG). History of myocardial infarction within 6 months of randomization. History of LVEF decline to below 50% during or after previous trastuzumab neo-adjuvant or adjuvant therapy. Significant cardiac murmurs either on examination or ECHO.
- History of prior exposure to doxorubicin >360 mg/m² (or equivalent). Use of oral, injected or implanted hormonal methods of contraception. Chronic daily use of corticoids (equivalent to >10 mg/day methylprednisolone) by oral intake (inhalation is permitted).
- Known hypersensitivity to any of the study drugs.
- Residual non-hematologic toxicity ≥ Grade 2 from prior therapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HLX02+docetaxel
|
8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
75 mg/m2 will be administered on Day 2, Cycle 1.then be given every 3 weeks on Day 1 of each subsequent cycle
|
Active Comparator: Herceptin®+docetaxel
|
75 mg/m2 will be administered on Day 2, Cycle 1.then be given every 3 weeks on Day 1 of each subsequent cycle
8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR 24
Time Frame: From time of First treatment to week 24
|
calculated as the proportion of patients with a best response of complete response (CR) or partial response (PR) from first assessment until Week 24 according to RECIST 1.1.
|
From time of First treatment to week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS up to 12 months
Time Frame: From time of first treatment to 12 months
|
The probability of being alive without documented progression up to 12 months after randomization
|
From time of first treatment to 12 months
|
ORR at Week 6, 12, 18, and 24 by CIR
Time Frame: From week 6 to week 24
|
the probability of being alive 12, 24, and 36 months after randomization
|
From week 6 to week 24
|
DoR
Time Frame: Up to 2 years
|
The time from first documentation of CR or PR to the first documentation of progression.
|
Up to 2 years
|
DCR
Time Frame: Up to 2 years
|
The proportion of patients who achieve CR, PR, or stable disease (SD) of at least 12 weeks
|
Up to 2 years
|
CBR
Time Frame: Up to 2 years
|
The proportion of patients who achieve CR, PR, or durable SD (SD ≥24 weeks)
|
Up to 2 years
|
Overall survival at 12, 24, and 36 months
Time Frame: From time of first treatment to 36 months
|
the probability of being alive 12, 24, and 36 months after randomization
|
From time of first treatment to 36 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2016
Primary Completion (Actual)
November 23, 2018
Study Completion (Actual)
September 28, 2021
Study Registration Dates
First Submitted
March 14, 2017
First Submitted That Met QC Criteria
March 17, 2017
First Posted (Actual)
March 20, 2017
Study Record Updates
Last Update Posted (Actual)
June 7, 2022
Last Update Submitted That Met QC Criteria
June 4, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HLX02-BC01
- 2016-000206-10 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
Clinical Trials on HLX02
-
Shanghai Henlius BiotechCompleted
-
Shanghai Henlius BiotechCompleted
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingBreast Ductal Carcinoma In SituUnited States, Canada, Puerto Rico, Korea, Republic of
-
Veana TherapeuticsUniversity of WashingtonRecruitingAnatomic Stage IV Breast Cancer AJCC v8 | HER2 Positive Breast Carcinoma | Metastatic Breast Carcinoma | Refractory Breast CarcinomaUnited States
-
National Cancer Institute (NCI)Gynecologic Oncology GroupCompletedRecurrent Uterine Corpus Carcinoma | Endometrial Adenocarcinoma | Stage III Uterine Corpus Cancer AJCC v7 | Stage IV Uterine Corpus Cancer AJCC v7 | ERBB2 Gene AmplificationUnited States
-
National Cancer Institute (NCI)Active, not recruitingMale Breast Carcinoma | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7United States, Puerto Rico
-
National Cancer Institute (NCI)CompletedRecurrent Breast Carcinoma | Invasive Breast Carcinoma | HER2/Neu Positive | Stage IV Breast Cancer AJCC v6 and v7United States
-
Jonsson Comprehensive Cancer CenterEli Lilly and Company; Genentech, Inc.RecruitingMetastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8 | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Recurrent Breast Carcinoma | Estrogen Receptor Positive | HER2/Neu Positive | Progesterone Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7 | Postmenopausal | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedAnatomic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | HER2-Positive Breast CarcinomaUnited States